The haemoglobin levels of patients with prostate cancer treated with radical radiotherapy


  • Jéssika Sthephane Crislene Mendes
  • Larissa Bluma Lopes
  • Livia de Castro Sbano
  • Rebeca Pimenta Martins Malvão
  • Giulia Nogueira Franca
  • Antonio Belmiro Rodrigues Campbell Penna
  • Angela Cristina Marinho Moreira
  • Ana Cláudia Marinho Cardoso
  • Carla Nogueira
  • Reynaldo Real Martins Júnior
  • Carlos Antonio da Silva Franca



radiotherapy, prostatic neoplasms, anemia


Introduction: The worldwide estimate points to prostate cancer as the second most frequent cancer in men worldwide, where radiotherapy has been an important modality of curative treatment in managing this neoplasia. The prevalence and impact of cancer-related anemia are not widely known, and it may be overlooked or considered clinically significant. It is believed that the outcomes and toxicity of radiotherapy in prostate cancer treatment may be influenced by blood hemoglobin levels. Objective: To evaluate hemoglobin levels in patients with prostate cancer before and after radiotherapy treatment. Methods: Retrospective, longitudinal study of patients diagnosed with malignant prostate neoplasms undergoing external radiotherapy. Hemoglobin levels were measured before radiotherapy and after treatment completion (20-40 days). Anemia was defined by the World Health Organization as men with values less than 13 g/dl. Prostate cancer recurrence risk classification was based on the National Comprehensive Cancer Network risk criteria. Results: Forty patients were evaluated with measurement of Hemoglobin levels before and after radiotherapy treatment. The mean age was 67 years. According to the risk group classification, 4 patients were low-risk (10%), 27 patients were intermediate-risk (67.5%), and 9 patients were high-risk (22.5%). The mean pre-radiotherapy Hemoglobin levels were 13.3 g/dL, and the mean post-radiotherapy Hemoglobin levels were 10.4 g/dL, p < 0.0001. Conclusion: In this study, a reduction in serum Hemoglobin levels was observed after radiotherapy, highlighting the need for better monitoring of these patients.


- Instituto Nacional de Câncer (Brasil). Estimativa 2023 : incidência de câncer no Brasil / Instituto Nacional de Câncer, Rio de Janeiro : INCA, 2022.

- Hofmann A, Aapro M, Fedorova TA, Zhiburt YB, Snegovoy AV, Kaganov, OI, Poddubnaya, IV. Patient blood management in oncology in the Russian Federation: Resolution to improve oncology care. Journal of Cancer Policy 2022;31:100315. DOI:

- Yu S, Tao X, Suyan Z and Hongbin X. Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS. Expert Opinion on Drug Safety 2023; DOI:

- Jordão RE, Bernardi JLD, Filho AAB. Prevalência de anemia ferropriva no Brasil: uma revisão sistemática. Rev. Paul. Pediatr. [online] 2009;27(1):90-98. DOI:

- National Comprehensive Cancer Network (NCCN). Guidelines. Prostate Cancer. Disponivel em:

- Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451-9. DOI:




How to Cite

MENDES, J. S. C.; LOPES, L. B.; SBANO, L. de C.; MALVÃO, R. P. M.; FRANCA, G. N.; PENNA, A. B. R. C.; MOREIRA, A. C. M.; CARDOSO, A. C. M.; NOGUEIRA, C.; MARTINS JÚNIOR, R. R.; FRANCA, C. A. da S. The haemoglobin levels of patients with prostate cancer treated with radical radiotherapy. Journal Archives of Health, [S. l.], v. 5, n. 1, p. 612–617, 2024. DOI: 10.46919/archv5n1-039. Disponível em: Acesso em: 24 jul. 2024.